These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19338077)

  • 1. Somatic and germline genetics at the JAK2 locus.
    Campbell PJ
    Nat Genet; 2009 Apr; 41(4):385-6. PubMed ID: 19338077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.
    Olcaydu D; Harutyunyan A; Jäger R; Berg T; Gisslinger B; Pabinger I; Gisslinger H; Kralovics R
    Nat Genet; 2009 Apr; 41(4):450-4. PubMed ID: 19287385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
    Kilpivaara O; Mukherjee S; Schram AM; Wadleigh M; Mullally A; Ebert BL; Bass A; Marubayashi S; Heguy A; Garcia-Manero G; Kantarjian H; Offit K; Stone RM; Gilliland DG; Klein RJ; Levine RL
    Nat Genet; 2009 Apr; 41(4):455-9. PubMed ID: 19287384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
    Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
    Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 haplotype 46/1 and JAK2 V617F allele burden in MPN: New evidence against the "hypermutability" hypothesis?
    Stolyar MA; Klimova OA; Gorbenko AS; Brenner EV; Titov SE; Ivanov MK; Olkhovskiy IA
    Int J Lab Hematol; 2018 Feb; 40(1):e8-e10. PubMed ID: 29134760
    [No Abstract]   [Full Text] [Related]  

  • 6. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.
    Jones AV; Chase A; Silver RT; Oscier D; Zoi K; Wang YL; Cario H; Pahl HL; Collins A; Reiter A; Grand F; Cross NC
    Nat Genet; 2009 Apr; 41(4):446-9. PubMed ID: 19287382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
    Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
    Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
    Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
    Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular insights into regulation of JAK2 in myeloproliferative neoplasms.
    Silvennoinen O; Hubbard SR
    Blood; 2015 May; 125(22):3388-92. PubMed ID: 25824690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms.
    Soler G; Bernal-Vicente A; Antón AI; Torregrosa JM; Caparrós-Pérez E; Sánchez-Serrano I; Martínez-Pérez A; Sánchez-Vega B; Vicente V; Ferrer-Marin F
    Ann Hematol; 2015 May; 94(5):789-94. PubMed ID: 25482455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms.
    Jäger R; Harutyunyan AS; Rumi E; Pietra D; Berg T; Olcaydu D; Houlston RS; Cazzola M; Kralovics R
    Am J Hematol; 2014 Dec; 89(12):1107-10. PubMed ID: 25196853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Navarro-Vázquez M; González-Carrillo ML
    Rev Invest Clin; 2006; 58(5):458-61. PubMed ID: 17408106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloproliferative Neoplasms: The Long Wait for JAK2-Mutant Clone Expansion.
    Luque Paz D; Ashcroft P; Skoda RC
    Cell Stem Cell; 2021 Mar; 28(3):359-361. PubMed ID: 33667352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?
    Anelli L; Zagaria A; Specchia G; Albano F
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
    Funakoshi-Tago M
    Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
    Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L
    Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P; Levine RL
    Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of JAK2, CBL, RUNX1, and NPM1 genes in familial aggregation of hematological malignancies.
    Hamadou WS; Bourdon V; Gaildrat P; Besbes S; Fabre A; Youssef YB; Regaieg H; Laatiri MA; Eisinger F; Mari V; Gesta P; Dreyfus H; Bonadona V; Dugast C; Zattara H; Faivre L; Jemni SY; Noguchi T; Khélif A; Sobol H; Soua Z
    Ann Hematol; 2016 Jun; 95(7):1043-50. PubMed ID: 27106701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.
    Tefferi A; Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Gangat N; Pardanani A
    Am J Hematol; 2019 Mar; 94(3):299-305. PubMed ID: 30516848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population.
    Syeed N
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3611-3615. PubMed ID: 31870101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.